A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by </=0.125 micro g of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% p...

Multidrug-resistant (MDR) Gram-negative organisms are a burden on the global health care system. The Tigecycline Evaluation and Surveillance Trial (TEST) is an ongoing global study designed to monitor the in vitro activities of tigecycline and a panel of marketed antimicrobials against a range of clinically significant pathogens. In this study, in vitro data are presented for MDR Acinetobacter ...

In the January 2007 issue of the Journal of Clinical Microbiology, Jones et al. reported a multicenter study of the tigecycline disk diffusion breakpoints of Acinetobacter spp., including multidrug-resistant (MDR) strains. The authors concluded that a breakpoint zone diameter of 16/ 12 mm to define susceptibility/resistance, respectively, instead of those proposed by the U.S. Food and Drug Admi...

Sir, We read with great interest the letter by Nix and Matthias 1 regarding pharmacokinetic considerations relating to tigecycline use in urinary tract infections (UTIs). We agree with the authors that tige-cycline should not be used for UTIs when other therapies including aminoglycosides, carbapenems and colistin are options; however, in rare situations, tigecycline may be considered. In a rec...

OBJECTIVE To measure the in-vitro activity of various antibiotics including tigecycline against Gram negative and positive nosocomial aerobic isolates. METHODS A total of 430 clinical isolates of both Gram positive (143) and negative (287) aerobic bacteria were used from 3 centres during the year 2006 and 2007. Minimum inhibitory concentration (MIC) was determined using broth micro dilution p...

This paper reviews the antimicrobial profile and available clinical data for the first member of the glycylcycline class, tigecycline. Emerging multi-drug resistance among gram-positive and gram-negative pathogens continues to limit the antibiotic armamentarium. Tigecycline, a derivative of minocycline, may provide a therapeutic option in select patients, given its broad spectrum of activity, i...

Tigecycline is a new glycylcycline antibiotic structurally similar to minocycline antibiotic. It has broad spectrum activity, including Staphylococcus aureus infections. This is the first study that evaluated the activity of Tigecycline against Staphylococcus aureus isolated from biological samples in Iran. In vitro activity of tigecycline against 160 Staphylococcus aureus including 99 methicil...

The Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor global longitudinal changes in bacterial susceptibility to a panel of antimicrobial agents, including tigecycline. In this study, we examine susceptibility among Gram-positive isolates collected from pediatric patients globally between 2004 and 2011. A total of 9,422 Gram-positive isolates were contributed by 1,255...

Tigecycline was initially approved by the U.S. Food and Drug Administration (FDA) in June 2005. We assessed the evolution of tigecycline in vitro activities since the initial approval of tigecycline for clinical use by analyzing the results of 7 years (2006 to 2012) of data from the SENTRY Antimicrobial Surveillance Program in the United States. We also analyzed trends over time for key resista...

Multidrug-resistant (MDR) and carbapenem-resistant (CR) Gram-negative pathogens are becoming increasingly prevalent around the globe. Polymyxins and tigecycline are among the few antibiotics available to treat infections with these bacteria but little is known about the frequency of their use. We therefore aimed to estimate the parenteral use of these two drugs in Veterans Affairs medical cente...